The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiopathy (TA-TMA) in adults and kids ages 2 years and up, ...
There’s a lot of debate about weight machines in the fitness world. Some people gravitate towards them because they seem a heck of a lot easier than cranking out some reps with a pair of dumbbells or ...
The Canadian Press on MSN
Canada's dream of hosting a men's World Cup dates back to 1976 Montreal Olympics
The quest for Canada to host a men's FIFA World Cup dates back some 50 years for Walter Sieber.
Snow in the forecast? These tested tools are our favorites for clearing paths and driveways—and they'll deliver or be ready for pickup within the week.
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA ® (narsoplimab-wuug) for the treatment of ...
Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent ...
It's been a long time coming: Four years after Omeros came up short in its bid to gain an FDA approval for stem cell transplant drug narsoplimab, the Seattle biotech has finally scored its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback